PhD fellowship in antibody-drug conjugate (ADC) engineering: internalization and lysosomal delivery
University of Copenhagen (Koebenhavns Universitet), Biotech Research and Innovation Centre (BRIC) / Finsen Laboratory
All verified opportunities · More from University of Copenhagen
Who can apply: An MSc (120 ECTS or equivalent) in pharmaceutical biotechnology, biotechnology or a closely related field, with an MSc thesis on antibody-drug conjugates or antibody-based cancer therapeutics and hands-on experience in antibody production, payload conjugation, cytotoxicity assays, flow cytometry and laboratory animal… What is funded: A salaried 3-year PhD fellowship at BRIC, part of a Novo Nordisk Foundation Distinguished Innovator project. Salary and pension follow the Danish state agreement for academics. Expected start is 15 January 2027. Deadline: 6 November 2026, 23.59 CET. Round: show=171624.
Read the full call and apply on the official page: University of Copenhagen (Koebenhavns Universitet), Biotech Research and Innovation Centre (BRIC) / Finsen Laboratory, official page.
Who can apply
- An MSc (120 ECTS or equivalent) in pharmaceutical biotechnology, biotechnology or a closely related field, with an MSc thesis on antibody-drug conjugates or antibody-based cancer therapeutics and hands-on experience in antibody production, payload conjugation, cytotoxicity assays, flow cytometry and laboratory animal work. The master's degree must be equivalent to a Danish master's degree. Excellent written and spoken English is required.
Stage dates
Online application via Apply now, 23.59 CET6 November 2026
Interviews expected in week 49 (2026)See the official page
Start 15 January 2027 or after agreement15 January 2027
Dates come from the funder's page for this round. When a round closes, the next round's dates replace these once the funder publishes them.